Tonix Pharmaceuticals Holding Corp logo

Tonix Pharmaceuticals Holding Corp

$ 0.57 +0.0231 (+4.2%) 04:00 PM EST
P/E:
At Loss
P/B:
0.08
Market Cap:
$ 25.67M
Enterprise V:
$ -87.63M
Volume:
1.84M
Avg Vol (2M):
4.01M
Also Trade In:
Volume:
1.84M
Market Cap $:
25.67M
PE Ratio:
At Loss
Avg Vol (2-Month):
4.01M
Enterprise Value $:
-87.63M
PB Ratio:
0.08
GF Score:
Year:
Embed
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
Tonix Pharmaceuticals Holding Corp is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio is composed of immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. Tonix's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500 which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Tonix's rare disease portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome.
Name Current Vs Industry Vs History
Cash-To-Debt 147.69
Equity-to-Asset 0.94
Debt-to-EBITDA -0.01
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0
Distress
Grey
Safe
Beneish M-Score 0
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 30.53
9-Day RSI 23.2
14-Day RSI 25.26
6-1 Month Momentum % -85.79
12-1 Month Momentum % -94.73

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 12.05
Quick Ratio 12.05
Cash Ratio 9.14

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -1051.4
Name Current Vs Industry Vs History
ROE % -47.65
ROA % -42.65
ROIC % -174.22
ROC (Joel Greenblatt) % -179.66
ROCE % -45.62

Financials (Next Earnings Date:2022-11-08 Est.)

TNXP's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:TNXP

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Embed

Valuation Box

Year:
Embed

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0
EPS (TTM) ($) -6.66
Beta 2.15
Volatility % 76.06
14-Day RSI 25.26
14-Day ATR ($) 0.075814
20-Day SMA ($) 0.73307
12-1 Month Momentum % -94.73
52-Week Range ($) 0.52 - 20
Shares Outstanding (Mil) 44.8

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Tonix Pharmaceuticals Holding Corp Filings

Document Form Filing Date
No Filing Data

Tonix Pharmaceuticals Holding Corp Analysis

Share your research

Headlines

See More
No news.